5+ day, 4+ hour ago   (368+ words) BiotechDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...

1+ week, 11+ hour ago   (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...

1+ week, 11+ hour ago   (359+ words) BiotechDispatch Australian biotech Immuron takes gut health treatment to the US market Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB....

1+ week, 11+ hour ago   (504+ words) BiotechDispatch Neurizon Therapeutics appoints Chris Bremer as chief executive to steer ALS drug through final trial stage Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new…...

1+ week, 4+ day ago   (338+ words) Prescient Therapeutics has reached an enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December. The Melbourne-based clinical-stage oncology company said…...

1+ week, 4+ day ago   (396+ words) Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place....

2+ week, 9+ hour ago   (279+ words) Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of ATH434 in multiple system atrophy. The Melbourne- and San Francisco-based biotechnology company said…...

2+ week, 6+ day ago   (394+ words) Nanosonics has entered financial year 2027 with continued growth from its trophon disinfection business, while advancing the commercial rollout of its CORIS endoscope reprocessing platform and commencing a new on-market share buyback of up to $40 million. Revenue rose 3 per cent to…...

2+ week, 6+ day ago   (418+ words) Avecho Biotechnology has appointed senior pharmaceutical executive Eve Williamson as a strategic business development consultant, bringing dedicated dealmaking capacity as the company seeks international partners for its CBD TPM soft-gel capsule for insomnia. The appointment comes as Avecho advances its…...

3+ week, 4+ day ago   (551+ words) Dimerix has received a US$10 million upfront payment from Everest Medicines under its commercial licensing agreement for its lead kidney disease candidate, DMX-200, adding further financial weight to the Melbourne biotechnology company’s push towards a pivotal Phase 3 readout. The payment, worth…...